<DOC>
	<DOCNO>NCT01961349</DOCNO>
	<brief_summary>This study design multi-centre , randomise , parallel-group , placebo-controlled , phase III confirmatory study . The study partially double-blinded : comparison Group 1 ( placebo group ) Group 2 ( ICI35,868 without EES0000645/A ) carry double-blind , comparison Group 1 ( placebo group ) Group 3 ( ICI35,868 EES0000645/A ) carry single-blind . The efficacy safety ICI35,868 without EES0000645/A sedation moderate diagnostic gastrointestinal endoscopy gastrointestinal endoscopic polypectomy evaluate .</brief_summary>
	<brief_title>Phase III Study ICI35,868 ( Diprivan ) With Without EES0000645/A ( SDS ) Gastrointestinal Endoscopy</brief_title>
	<detailed_description />
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<criteria>1.Provision write informed consent prior studyrelated procedures/examinations 2.Aged 20 year old 3.Subjects plan undergo nonemergent EGD colonoscopy , include gastrointestinal endoscopic polypectomy shall complete within 1 hour ( exclude endoscopic submucosal dissection ultrasonic endoscope , pernasal endoscope , etc. ) . 1. involvement planning and/or conduct study ( apply sponsor 's employee and/or staff study site ) 2 . Subjects underwent endoscopic procedure ICI35,868 ( propofol ) administration within 1 year . 3 . Participation another clinical study investigational product within 4 week prior randomisation . 4 . Baseline ( Visit 1 ) blood oxygen saturation ( SpO2 ) &lt; 90 % ( room air ) 5 . ASA III , IV , V VI ; Subject serious disease cardiovascular , respiratory , renal , liver , pancreatic endocrine function .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>sedation , propofol , gastrointestinal endoscopy</keyword>
</DOC>